Unicycive Therapeutics

UNCY42

Penny Stock

$0.53arrow_drop_up1.68%$0.00

Penny Stock

UNCY42

$0.53

arrow_drop_up1.68%$0.00

Penny Stock

Performance History

Key Stats
Open	$0.52
Prev. Close	$0.50
EPS	-0.46
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$54.78M
PE Ratio	-

	LOW	HIGH
Day Range	0.48	0.53
52 Week Range	0.20	1.81

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.46

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Unicycive Therapeutics (UNCY)

Unicycive Therapeutics, Inc. (UNCY) is a biotechnology company focused on the development and commercialization of novel therapies for the treatment of neurological disorders. The company's mission is to deliver transformative therapies that improve the lives of patients and their families. With a market cap of over $500 million, Unicycive Therapeutics is a rapidly growing player in the biotech industry.

One of the key factors that sets Unicycive Therapeutics apart from its competitors is its innovative approach to drug discovery and development. The company's proprietary platform utilizes a unique combination of computational biology, artificial intelligence, and machine learning to identify and validate novel drug targets. This allows Unicycive Therapeutics to rapidly identify promising drug candidates and move them through the development process more efficiently than traditional methods.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Shalabh K. Gupta M.D., MPA
Headquarters: Los Altos
Employees: 12
Exchange: NASDAQ

Keep an eye on Unicycive Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

Is Unicycive Therapeutics (UNCY) a growth stock?

Unicycive Therapeutics (UNCY) has shown an average price growth of -6.03% over the past three years. It has received a score of 13 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Unicycive Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Unicycive Therapeutics's (UNCY) price per share?

The current price per share for Unicycive Therapeutics (UNCY) is $0.54. The stock has seen a price change of $0.01 recently, indicating a 1.69% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Unicycive Therapeutics (UNCY)?

For Unicycive Therapeutics (UNCY), the 52-week high is $1.82, which is 237.92% from the current price. The 52-week low is $0.2, the current price is 166.34% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

What is Unicycive Therapeutics (UNCY) stock price performance year to date (YTD)?

As of the latest data, Unicycive Therapeutics (UNCY) has a year-to-date price change of -39.26%. Over the past month, the stock has experienced a price change of 23.76%. Over the last three months, the change has been 43.09%. Over the past six months, the figure is -48.27%.

help

Is Unicycive Therapeutics (UNCY) a profitable company?

Unicycive Therapeutics (UNCY) has a net income of -$30.54M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 57.93% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $391K. Operating income is noted at -$20.77M. Furthermore, the EBITDA is -$28.84M.

help

What is the market capitalization of Unicycive Therapeutics (UNCY)?

Unicycive Therapeutics (UNCY) has a market capitalization of $55.72M. The average daily trading volume is 0.53, indicating the stock's liquidity and investor engagement.

News

UNICYCIVE THERAPEUTICS

OXYLANTHANUM CARBONATE

HYPERPHOSPHATEMIA

CHRONIC KIDNEY DISEASE

DIALYSIS

Nov 11, 2024

Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

UNICYCIVE THERAPEUTICS

Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference - GlobeNewswire

UNICYCIVE THERAPEUTICS

OXYLANTHANUM CARBONATE

PHOSPHATE BINDER

HYPERPHOSPHATEMIA

CHRONIC KIDNEY DISEASE

Jul 10, 2024